Phase 1 Lung Cancer Trial, Recruiting NCT05136846 Sponsor: Ohio State University Comprehensive Cancer Center Condition: Lung Cancer
Back to Lung Cancer

Phase 1 Lung Cancer Trial, Recruiting

NCT05136846
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Side effects from any previous cancer treatments must have mostly resolved (to a mild level or below) before joining, except for hair loss
  • Blood cell counts, liver function, and kidney function must meet specific levels measured by blood tests (confirm exact values with trial site)
  • People aged 18 or older
  • People diagnosed with non-small cell lung cancer (NSCLC), confirmed by tissue or cell testing
  • People with stage II or III NSCLC that cannot be treated with surgery, either because of where the tumour is or because surgery is not safe for that person medically
  • People with a small number of areas where cancer has spread (up to 5 sites total, with up to 10 brain spots counted as just 1 site), where the medical team recommends radiation treatment to the chest
  • People whose lung cancer has come back in the chest area after previous surgery, where the medical team recommends radiation treatment
  • People who have had specific scans completed, including a PET-CT scan (or CT scan of the chest, abdomen, and pelvis with contrast dye) and a brain scan (MRI preferred, or CT with contrast)
  • People who have had recent blood tests, physical examination, and vital signs checked within 14 days of joining
  • People with a general health and activity level rated 0, 1, or 2 on a standard medical scale (meaning able to care for oneself, with activity ranging from fully active to limited strenuous activity)
  • People with no history of complete heart conduction block, liver disease such as cirrhosis, glaucoma, or a condition called priapism
  • People who have fully healed from any chest surgery and are at least 3 weeks past that procedure before starting treatment
  • People who are able to give written consent before any study procedures begin
  • Women who could potentially become pregnant must have a negative pregnancy test within 14 days of joining
  • Women who are breastfeeding may only participate if breastfeeding is stopped before treatment begins
  • People of reproductive age must be willing to use effective contraception or abstain from sex during treatment and for 6 months after the last radiation dose
  • People planning to receive chemotherapy alongside radiation must be considered suitable for standard chemotherapy by their oncologist

For the optional MRI imaging part of the trial:

  • People who consent to the main trial and also agree to take part in the optional MRI imaging study

Who may not be able to join:

  • People who have had a pneumonectomy (surgical removal of an entire lung)
  • People with a history of active connective tissue disease (such as scleroderma) or a lung scarring condition called idiopathic pulmonary fibrosis
  • People who have had previous radiation therapy in an area that would overlap with the new radiation treatment planned
  • People who are breastfeeding and plan to continue during treatment, or who have a positive pregnancy test
  • People with liver problems causing jaundice, or whose liver blood test results do not meet the required levels
  • People with serious unstable medical or psychiatric conditions that could affect their safety or ability to follow the study, including:
    • Unstable chest pain or heart failure requiring hospital admission in the past 6 months
    • A serious heart attack in the past 6 months
    • AIDS (as defined by current health authority guidelines)
    • A severe flare-up of a lung condition, or breathing problems serious enough to require hospitalisation, within 30 days of joining
  • People currently taking nitrate medications (such as nitroglycerin), or who have taken them within 30 days of starting the study treatment
  • People currently taking sildenafil (Viagra) who are not willing to stop use for 2 days before starting a study drug called papaverine, throughout the study, and for 2 days after the last dose of papaverine

For the optional MRI imaging part of the trial:

  • People with medical reasons they cannot have an MRI scan (such as a pacemaker, certain metal implants, aneurysm clips, or weighing more than 350 pounds)
  • People with severe anxiety or claustrophobia related to MRI scanning, even with medication to help
  • People who use supplemental oxygen and are unable to stop using it for a few hours at a time, or who need oxygen when lying down

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jeremey Brownstein, MD, Ohio State University Comprehensive Cancer Center

Phone: 800-293-5066

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Ohio State University Comprehensive Cancer Center
Registry
ClinicalTrials.gov
Start date
6 December 2021
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Maximally tolerated dose (MTD) of papaverine (PPV) in combination with chemoradiation treatment (CRT) or definitive hypofractionated radiation therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov